Table 2:
Cohort Characteristics and unadjusted hazard ratios (HR) for chemotherapy-related ovarian failure (N=115)
| Cohort characteristic | N (%) | Unadjusted HR (95% CI) |
|---|---|---|
| Median age at chemotherapy (range), years | 39.7 (20.8–46.1) | 1.2 (1.1–1.3) |
| Race Caucasian African American Other |
79 (68.7) 15 (13.0) 21 (18.3) |
ref 1.3 (0.51–3.6) 1.2 (0.47–2.9) |
| Income > $60,000 ≤ $60,000 Declined to report |
65 (58.6) 33 (29.7) 13 (11.7) |
ref 0.56 (0.22–1.4) 1.02 (0.35–3.0) |
| Education High school College Masters/doctorate |
19 (16.5) 61 (53.0) 32 (27.8) |
ref 0.69 (0.28–1.7) 0.72 (0.27–1.9) |
| Smoker | 8 (7.0) | 0.89 (0.21–3.7) |
| Cancer Type Ductal Lobular Mixed |
107 (93.0) 3 (2.6) 4 (3.5) |
ref 1.3 (0.17–9.2) 1.1 (0.15–8.1) |
| ER or PR+ | 75 (65.2) | 1.6 (0.71–3.6) |
| Cancer stage 1 2 3 |
26 (22.6) 58 (50.4) 26 (22.6) |
ref 0.57 (0.25–1.3) 0.96 (0.37–2.5) |
| Her2 neu+ | 24 (20.9) | 1.1 (0.47–2.5) |
| Chemotherapy regimen Adriamycin, cyclophosphamide ± paclitaxel Docetaxel, cyclophosphamide |
85 (73.9) 30 (26.1) |
ref 1.1 (0.49–2.3) |
| Tamoxifen | 57 (51.8) | 1.8 (0.86–3.9) |
| Radiation | 82 (73.2) | 1.3 (0.57–3.1) |
*
Due to missing data, not all variables sum to 115 participants